> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Sage ANDA for Generic Apokyn Cartridges
- URL: https://www.fdaweb.com/fda-oks-sage-anda-for-generic-apokyn-cartridges/
- Published: 2022-02-25T12:00:00.000Z
- Updated: 2026-09-14T17:34:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151247

FDA has approved a Sage Chemical ANDA for the first generic version of Mylan’s Apokyn (apomorphine hydrochloride injection) drug cartridges to treat hypomobility “off” episodes (end-of-dose wearing off and unpredictable “on/off” episodes) associated with advanced Parkinson’s disease. FDA notes that the approval is for Sage’s drug cartridges, which must be used with a separately obtained Apokyn Pen. “Patients should first obtain the prescribed Apokyn Pen through a specialty pharmacy before being prescribed the generic apomorphine hydrochloride injection,” it says.

FDA says the most common side effects associated with apomorphine hydrochloride injection are yawning, drowsiness/somnolence, dyskinesias (involuntary muscle movements), dizziness/postural hypotension, rhinorrhea (runny nose), nausea, vomiting, hallucination/confusion, and edema/swelling of extremities.